Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oncolytic adenovirus AdAPT-001

A replication competent human attenuated adenoviral vector, TAV-255, modified to express a human transforming growth factor beta (TGF-b) trap fusion protein that neutralizes TGF-b, with potential oncolytic, immunomodulating and antineoplastic activities. Upon administration, oncolytic adenovirus AdAPT-001 selectively binds to and replicates in tumor cells and induces tumor cell lysis. In addition, tumor cell lysis releases a variety of tumor-associated antigens (TAAs) which may potentially result in the activation of a systemic immune response against the TAAs-expresssing tumor cells. AdAPT-001 has been attenuated to prevent replication in healthy cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:oncolytic virus AdAPT-001
Code name:AdAPT 001
AdAPT-001
AdAPT001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search